Seeking Alpha
View as an RSS Feed

Stock Reversals  

View Stock Reversals' Comments BY TICKER:
Latest  |  Highest rated
  • Trevena's Q4 2014 Results Conference Call - What We Learned [View article]
    We continue to like this one long term, our report came out March 12th at 5.75... nice pullback this week, it got pretty overheated with retail chasers... slow and steady wins the race...
    Mar 28, 2015. 12:30 PM | Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    Retail traders set stop losses and then the computers run them often... at our SRP service we advised our members to sell 1/2 their CLDN at 26-27 about 2 weeks ago during the huge run up after Roth put that fat target on the shares. We had been buying from 16-18.... so we are long 1/2 now into MYDICAR data... this is really the best way to play these data related stocks. That said, we feel good about the upside here... but we never bet the farm on one stock...
    Mar 27, 2015. 04:30 PM | Likes Like |Link to Comment
  • T2 Biosystems: Impressive Opportunity With Sepsis Diagnosis [View article]
    already long at SRP I wrote a full report 2 weeks ago.
    Mar 26, 2015. 10:11 AM | 2 Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    80... at least
    Mar 24, 2015. 10:41 PM | 1 Like Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    No worries we as you know are long from much lower levels and our target was $80 upon approval, $35 plus if MYDICAR data hits...
    Mar 24, 2015. 03:23 PM | Likes Like |Link to Comment
  • Trevena's Q4 2014 Results Conference Call - What We Learned [View article]
    Here is our work from March 12th
    http://seekingalpha.co...

    We sent it to our SRP members and also SR members as well same morning, but posted it on our insta blog since we made it available to the free members and the public.
    Mar 23, 2015. 07:34 PM | Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    Analysts are using 36,000 in their models not 75,000. Also , its a single dose and penetration would take quite some time. Nonetheless, we remain bullish
    Mar 23, 2015. 07:28 PM | Likes Like |Link to Comment
  • Trevena's Q4 2014 Results Conference Call - What We Learned [View article]
    We wrote a full report on this company several days before your Seeking Alpha piece hit and we are long from about 5 75
    Mar 23, 2015. 03:31 PM | Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    We sold 1/2 our position at our SRP service and held 1/2, so that is how we are playing it. We took 50% profits and will ride into MYDICAR.
    Mar 22, 2015. 09:02 PM | Likes Like |Link to Comment
  • Cellectis on deck for what should be a very strong IPO [View news story]
    We wrote up Cellectis for our subscribers in January but via the CMVLF symbol which basically buys you the french listed stock in US dollars. Issue being currency risk, but from our $26 report we are nearing $40 in US dollars just 2 months or so later ahead of the IPO. It was a great way to get long before the IPO. Those who did some digging would have noted the quiet IPO announcement, which didnt show up on major press release distribution. We plan to hold obviously at this point.
    Mar 21, 2015. 11:19 AM | Likes Like |Link to Comment
  • Celladon's Cardiovascular Fast Track MYDICAR Candidate Could Provide Upside [View article]
    cholesterol does not by itself cause inflammation of the artery walls, that is caused by improper diet, sugars, processed foods that grind up against the wall and cause them to slowly become inflamed. Normally cholesterol would flush right through a normal artery wall and flush out... the walls are the issue...
    Mar 18, 2015. 01:47 PM | 1 Like Like |Link to Comment
  • Trevena Inc: Profitable To You And Disruptive To Everyone Else [View article]
    We wrote up a full research report last Thursday to our entire group of subscribers and put it on our Seeking Alpha blog so you are a few days late
    Mar 17, 2015. 10:43 AM | Likes Like |Link to Comment
  • Ziopharm - Update: A New Strong Competitor In The CarT Space And Other Areas With More Than 50 To 100 Percent Future Potential Upside Move In Price Due To Many Catalysts Ahead Near And Long Term [View instapost]
    Great job
    Mar 15, 2015. 08:20 AM | 1 Like Like |Link to Comment
  • IPO Lockup Expiration: T2 Biosystems, Inc. [View article]
    Unlikely to stay down for long folks...
    Mar 14, 2015. 08:51 AM | 1 Like Like |Link to Comment
  • Cellectis: Finding Value In A Crowded CAR-T Space [View article]
    We recommended this with a full report in January to our SRP members at 25.60, it ran to 33. When it dipped back to 26 ranges we bought the dip to add to our position. Its been to 39 and we told our members it would be worth 40 after the IPO. The euro currency translation has caused a 10% drop in the US Dollar price alone or the stock would be 37 or so now... We felt the plant sciences division was being given away for free and would get spun out at some point. We also liked their Cell editing patent portfolio and the Pfizer and Servier tie up... good stuff... we remain long along with ZIOP, CLDN and others...
    Mar 11, 2015. 08:26 AM | 4 Likes Like |Link to Comment
COMMENTS STATS
291 Comments
244 Likes